AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...

Investing.com -- { {6365|Gilead Sciences (NASDAQ: GILD )}} stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

Gilead Sciences Share Price Analysis Shares of Gilead Sciences were trading at $105.51 as of April 22. Over the last 52-week period, shares are up 61.94%.

Gilead Sciences posted better-than-expected top- and bottom-line results in the latest quarter, which the company credited to its virology and oncology segments. The biopharmaceutical company ...

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 Business Wire Jul 24, 2025, 1:05:00 PM ...

Gilead Sciences (GILD -0.93%) stock has been a standout among biotech companies over the past year, with its shares up more than 36%. Over the past decade, its shares delivered a total return of a ...